MedTrace Logo

Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy

NCT04582591 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2022-02-08

No results posted yet for this study

Summary

This protocol describes a phase II trial investigating the efficacy of CBD in paclitaxel- and oxaliplatin-induced peripheral neuropathy. The trial uses multiple assessments such as validated PRO-questionnaires and multifrequency vibrometry.

Conditions

  • Chemotherapy-induced Peripheral Neuropathy

Interventions

DRUG

Cannabidiol 100 MG/ML

Patients receive cannabidiol before and after treatment with chemotherapy

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Jørn Herrstedt, DMSc · Zealand University Hospital / University of Copenhagen

  • Sebastian W Nielsen, MD · Zealand University Hospital / University of Copenhagen

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2022-01-05
Completion
2023-08-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04582591 on ClinicalTrials.gov